Lupin Limited (NSE: LUPIN) secures U.S. FDA approval for Sodium Sulfate, Magnesium Sulfate, and Potassium Chloride Tablets, marking a significant milestone.
Max India Limited (MAXIND) reports Q4FY26 revenue up 44%, strong growth in residences, services, and AGEasy.
Zydus Lifesciences Limited (ZYDUSLIFE) receives US FDA Priority Review for Saroglitazar NDA to treat Primary Biliary Cholangitis (PBC).
Indoco Remedies Limited (INDOCO) receives EU GMP certification for its Baddi Plant III, underscoring commitment to high-quality pharmaceutical manufacturing.
Themis Medicare Limited (THEMISMED) reports Q4 FY26 results with revenue up 6.7% YoY and PAT turning positive.
CORONA Remedies Limited (CORONA) secures EU-GMP accreditation for its Hormone and Oral Solid Dosage facilities, boosting its global market expansion.
Dr. Reddy's Laboratories Ltd. (NSE: DRREDDY) to celebrate 25 years on NYSE with Closing Bell ceremony.
Alkem Laboratories Limited (ALKEM) reports record high EBITDA and strong revenue growth for Q4 & FY26, with notable performance in domestic and international.
Lupin Limited (LUPIN) shares positive Phase 1 data on LNP8701, a novel SOS1 inhibitor, accepted for ASCO Annual Meeting 2026.
Lupin Limited (LUPIN) receives Establishment Inspection Report (EIR) from U.S. FDA for its Ankleshwar facility, highlighting quality excellence.